The Pharmacy Times® Chronic Kidney Disease Resource Center is a comprehensive resource for clinical news and expert insights on issues related to long-term disease of the kidneys leading to renal failure.
September 3rd 2025
Compared with rivaroxaban, abelacimab significantly lowered bleeding risk in patients (AF) regardless of kidney function.